Trial Profile
Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolaemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Acronyms ODYSSEY-OLE
- Sponsors Sanofi
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 18 Nov 2017 This study has been completed in Portugal (End Date: 2017-06-30).
- 15 Nov 2017 Results of analysis assessing long-term adherence to alirocumab and background lipid-lowering therapies during open label extension period presented at the 90th Annual Scientific Sessions of the American Heart Association